Ziphius Vaccines is pioneering the development of self-amplifying RNA (saRNA) technologies, which offer significant advantages over traditional mRNA platforms. The saRNA molecules possess the unique ability to replicate within cells, allowing them to produce multiple copies of the desired protein from a single transcript. This self-replicating feature enables the generation of higher protein expression levels at lower doses, making saRNA a powerful tool for creating prophylactic vaccines against infectious diseases and gene supplementation therapies for rare genetic disorders. The technology is designed to elicit robust immune responses while maintaining a high safety profile, as the RNA does not integrate into the host genome and is rapidly degraded by cellular processes.

To facilitate the effective delivery of saRNA, Ziphius employs lipid nanoparticles (LNPs), which protect the RNA from degradation and ensure its stability and proper encapsulation. The company has developed an in-house LNP library specifically tailored for saRNA delivery, optimizing the formulation for various administration routes and targeting specific organs and tissues. This innovative approach not only enhances the efficacy of the vaccines and therapies but also minimizes potential toxicity. By leveraging these advanced technologies, Ziphius aims to rapidly respond to public health needs and create a new generation of medical tools that can address both infectious diseases and genetic disorders.

Belgium

Ziphius Vaccines is a biopharmaceutical company, dedicated to develop saRNA vaccines and therapeutics. Ziphius focuses on both vaccines for infectious diseases and gene supplementation therapies for rare genetic disorders. Since our founding in 2019, Ziphius has worked to develop and validate its self-amplifying RNA and LNP platforms. Currently, these platforms are being used to rapidly expand our pipeline and move forward multiple preclinical development programs towards the clinic.

Ziphius Vaccines

Company Details